SOLICITATION NOTICE
B -- Glycomics Studies; providing comprehensive CDG screening
- Notice Date
- 8/4/2014
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2014-210-DLM
- Archive Date
- 8/28/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Children's Hospital of Philadelphia, Room 5NW55, 5th Floor, 34th & Civic Center Boulevard, Philadelphia, Pennsylvania 19104 to provide Glycomics Studies; providing comprehensive CDG screening for NHGRI. Procurement: 1. To provide Glycomics Studies; providing comprehensive CDG screening including -carbohydrate deficient transferrin analysis, N-glycan analysis, 0-glycan analysis and free oligosaccharide analysis in both body fluids and cultured cells for NIH Undiagnosed Disease Program. Background: The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency seeking fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Institutes of Health Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. The UDP was established to evaluate participants who have undiagnosed medical conditions. UDP participants have generally received extensive diagnostic workups before traveling to the NIH and often have numerous and/or complex medical problems. The UDP program makes use of a diverse set of diagnostic and research techniques both to attempt to find a diagnosis and to generate research projects to advance medical knowledge. This is a follow-on contract for the laboratory of Dr. Miao He at the Children's Hospital of Philadelphia (CHOP) and the Palmieri Metabolic Disease Laboratory to provide cutting edge methodology for untargeted detection of pathological changes in the lipid glycosylation, protein-glycosylation and metabolic profiles of cerebrospinal fluid, plasma, urine and cultured fibroblasts from individuals with neurological disorders. The Children's Hospital of Philadelphia (CHOP) metabolic disease laboratory has developed a number of assays that are much more sensitive than previously available. The laboratory has provided comprehensive CDG screening including carbohydrate deficient transferrin analysis, N-glycan analysis, O-glycan analysis and free oligosaccharide analysis in both body fluids and cultured cells for the NIH Undiagnosed Diseases Program. This laboratory has also taken a lead in the development of assays that are untargeted and can also be used in any body fluid in order that they can be applied to populations with unknown disorders so that new biomarkers can be used to identify novel defects. This technology will continue to support the research needs of the UDP to identify new and rare diseases. Purpose and Objectives : The purpose of this acquisition is to provide metabolic pathway analysis on body fluids from patients in the Undiagnosed Disease Program. This analysis will determine how disease mutations and changes in or accumulation of biomarker compounds elicits patient disease. The Michael J Palmieri Metabolic Laboratory at The Children's Hospital of Philadelphia (CHOP) is a CLIA certified laboratory that analyzes approximately 10,000 samples a year for the measurement of targeted and untargeted biomarkers and that can lead to metabolic disease. Period of Performance : September 1, 2014 through August 31, 2016 Project Description : Requirements for this acquisition are as follows : • Contractor shall perform carbohydrate deficient transferrin analysis by affinity purification and LC-QTOF analysis. • Contractor shall perform untargeted N-glycan analysis on UDP patient plasma and CSF samples by MALDI-TOF; o Samples that show deviations must be further analyzed using targeted approaches by LC-QTOF. • Contractor shall perform untargeted O-glycan analysis in UDP patient plasma and CSF samples by MALDI-TOF; o Samples that show O-glycan disorder profiles must be further analyzed using targeted approaches by LC-QTOF analysis. • Contractor shall perform untargeted free oligosaccharide analysis on UDP patient urine samples by MALDI-TOF. o In-depth analysis will be performed by LC-QTOF. • Contractor shall perform glycomics analysis in cultured fibroblasts from patients with abnormalities in blood and urine; o N-glycan and O-glycan profiles of cell pellet will be measured by MALDI-TOF. o Oligosaccharides may be measured in the cell pellets and culture media as needed. • Contractor shall submit research notes, results and interpretations to the NIH UDP information analysis system (UDPICS). Regulatory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source. CLOSING STATEMENT: Industry Classification (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology) and small business size standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-76 (July 25, 2014). This requirement is under the Simplified Acquisition Threshold of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received August 13, 2014, 8:00 A.M. Eastern Time and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2014-210-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency." Faxes will not be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2014-210-DLM/listing.html)
- Place of Performance
- Address: Contractor's Location, United States
- Record
- SN03449085-W 20140806/140804235202-8ea001d9c8627960600cc75a2c8fa686 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |